Publications by authors named "Luca Gelsomino"

Article Synopsis
  • Endocrine therapy improves outcomes for ERα+ breast cancer, but resistance remains a key challenge, often linked to mutations like Y537S in the hormone-binding domain of ERα.
  • Researchers conducted coculture experiments to study interactions between mutant breast cancer cells (MCF-7YS) and fibroblasts (both normal and cancer-associated) to see how these interactions influence cancer progression.
  • The study found that the Y537S mutation led to changes in fibroblast behavior and protein expression, with increased YAP1 involvement, suggesting that mutant breast cancer cells can enhance their growth and invasion capabilities through interactions with the tumor microenvironment.
View Article and Find Full Text PDF

Circulating extracellular vesicle (EV)-derived microRNAs (miRNAs) are now considered the next generation of cancer "theranostic" tools, with strong clinical relevance. Although their potential in breast cancer diagnosis has been widely reported, further studies are still required to address this challenging issue. The present study examined the expression profiles of EV-packaged miRNAs to identify novel miRNA signatures in breast cancer and verified their diagnostic accuracy.

View Article and Find Full Text PDF

Obesity, defined as the abnormal or excessive expansion of white adipose tissue, has reached pandemic proportions and is recognized as an important health concern since it is a common root for several comorbidities, including malignancies. Indeed, the current knowledge of the white adipose tissue, which shifts its role from an energy storage tissue to an important endocrine and metabolic organ, has opened up new avenues for the discovery of obesity's effects on tumor biology. In this review, we will report the epidemiological studies concerning the strong impact of obesity in several types of cancer and describe the mechanisms underlying the heterotypic signals between cancer cell lines and adipocytes, with particular emphasis on inflammation, the insulin/IGF-1 axis, and adipokines.

View Article and Find Full Text PDF

Over the last two decades, obesity has reached pandemic proportions in several countries, and expanding evidence is showing its contribution to several types of malignancies, including breast cancer (BC). The conditioned medium (CM) from mature adipocytes contains a complex of secretes that may mimic the obesity condition in studies on BC cell lines conducted in vitro. Here, we report a transcriptomic analysis on MCF-7 BC cells exposed to adipocyte-derived CM and focus on the predictive functional relevance that CM-affected pathways/processes and related biomarkers (BMs) may have in BC response to obesity.

View Article and Find Full Text PDF
Article Synopsis
  • Adiponectin, a protein secreted by fat cells, is linked to the growth and spread of ERα-positive breast cancer by promoting cell proliferation and enhancing E-cadherin expression through the ERα/LKB1 complex.
  • In lab cultures, adiponectin increases E-cadherin levels, which is crucial for cancer cell growth; when E-cadherin is silenced, the growth effects of adiponectin disappear.
  • Adiponectin treatment leads to altered cell polarity as LKB1 and Cdc42 localize in the nucleus instead of working in the cytosol, resulting in greater breast cancer growth and increased metastasis in animal models.
View Article and Find Full Text PDF

Background: The incidence of obesity, a known risk factor for several metabolic and chronic diseases, including numerous malignancies, has risen sharply in the world. Various clinical studies demonstrate that excessive Body Mass Index (BMI) may worsen the incidence, prognosis, and mortality rates of breast cancer. Thus, understanding the link tying up obesity and breast cancer onset and progression is critically important, as it can impact patients' survival and quality of life.

View Article and Find Full Text PDF

Tumor extracellular vesicles (EVs), as endocytic vesicles able to transport nucleic acids, proteins, and metabolites in recipient cells, have been recognized fundamental mediators of cell-to-cell communication in breast cancer. The biogenesis and release of EVs are highly regulated processes and both the quantity of EVs and their molecular cargo might reflect the metabolic state of the producing cells. We recently demonstrated that the adipokine leptin, whose circulating levels correlate with adipose tissue expansion, is an inducer of EV release from breast cancer cells.

View Article and Find Full Text PDF
Article Synopsis
  • * The renin-angiotensin system (RAS) plays a significant role in glioblastoma by promoting local estrogen production and enhancing tumor growth through Angiotensin II signaling.
  • * Losartan, an RAS blocker, can counteract the negative effects of Ang II, including immunosuppression and increased local estrogen, suggesting it may be a useful addition to glioblastoma treatment strategies.
View Article and Find Full Text PDF

The incidence of obesity, a recognized risk factor for various metabolic and chronic diseases, including numerous types of cancers, has risen dramatically over the recent decades worldwide. To date, convincing research in this area has painted a complex picture about the adverse impact of high body adiposity on breast cancer onset and progression. However, an emerging but overlooked issue of clinical significance is the limited efficacy of the conventional endocrine therapies with selective estrogen receptor modulators (SERMs) or degraders (SERDs) and aromatase inhibitors (AIs) in patients affected by breast cancer and obesity.

View Article and Find Full Text PDF
Article Synopsis
  • Extracellular vesicles (EVs) from mature adipocytes enhance breast cancer cell malignancy by promoting growth, motility, and invasion, particularly linked to HIF-1α activity.
  • The study shows that these EVs can aid breast cancer cells in metastasizing to the lungs in mouse models.
  • Blocking HIF-1α activity or depleting EVs from obese adipocytes can hinder the aggressive behavior of breast cancer cells, offering a potential therapeutic target in obesity-related cancer progression.
View Article and Find Full Text PDF

Breast cancer is the most common solid malignancy diagnosed in females worldwide, and approximately 70% of these tumors express estrogen receptor α (ERα), the main biomarker of endocrine therapy. Unfortunately, despite the use of long-term anti-hormone adjuvant treatment, which has significantly reduced patient mortality, resistance to the endocrine treatments often develops, leading to disease recurrence and limiting clinical benefits. Emerging evidence indicates that extracellular vesicles (EVs), nanosized particles that are released by all cell types and responsible for local and systemic intercellular communications, might represent a newly identified mechanism underlying endocrine resistance.

View Article and Find Full Text PDF
Article Synopsis
  • Activation of peroxisome proliferator-activated receptor γ (PPARγ) by various ligands shows potential tumor-suppressing effects in several cancers, particularly breast cancer.
  • The breast tumor microenvironment (TME), which includes both neoplastic epithelial cells and surrounding stroma, plays a crucial role in cancer development and progression.
  • The review emphasizes the significance of PPARγ in the breast TME, suggesting that PPARγ ligands may be promising agents in breast cancer treatment strategies.
View Article and Find Full Text PDF

Estrogen receptor alpha gene (ESR1) mutations occur frequently in ER-positive metastatic breast cancer, and confer clinical resistance to aromatase inhibitors. Expression of the ESR1 Y537S mutation induced an epithelial-mesenchymal transition (EMT) with cells exhibiting enhanced migration and invasion potential in vitro. When small subpopulations of Y537S ESR1 mutant cells were injected along with WT parental cells, tumor growth was enhanced with mutant cells becoming the predominant population in distant metastases.

View Article and Find Full Text PDF

Peroxisome proliferator-activated receptor gamma (PPARγ), belonging to the nuclear receptor superfamily, is a ligand-dependent transcription factor involved in a variety of pathophysiological conditions such as inflammation, metabolic disorders, cardiovascular disease, and cancers. In this latter context, PPARγ is expressed in many tumors including breast cancer, and its function upon binding of ligands has been linked to the tumor development, progression, and metastasis. Over the last decade, much research has focused on the potential of natural agonists for PPARγ including fatty acids and prostanoids that act as weak ligands compared to the strong and synthetic PPARγ agonists such as thiazolidinedione drugs.

View Article and Find Full Text PDF

Aromatase inhibitors (AIs) represent the standard anti-hormonal therapy for post-menopausal estrogen receptor-positive breast cancer, but their efficacy is limited by the emergence of AI resistance (AI). Exosomes act as vehicles to engender cancer progression and drug resistance. The goal of this work was to study exosome contribution in AI mechanisms, using estrogen-dependent MCF-7 breast cancer cells as models and MCF-7 LTED (Long-Term Estrogen Deprived) subline, modeling AI.

View Article and Find Full Text PDF

In recent decades, the study of exosome biology has gained growing interest, representing an active area of cancer research with many potential clinical applications. Exosomes are small lipid bilayer particles released by cells with pleiotropic functions that have been reported to regulate the complex intracellular pathway involved in all steps of breast cancer development-from initiation to progression toward a metastatic dissemination. Particularly, the role of these microvesicles has been explored in metastasis, which represents the leading cause of breast cancer morbidity and mortality worldwide.

View Article and Find Full Text PDF

Aberrant leptin (Ob) signaling, a hallmark of obesity, has been recognized to influence breast cancer (BC) biology within the tumor microenvironment (TME). Here, we evaluated the impact of leptin receptor (ObR) knockdown in affecting BC phenotype and in mediating the interaction between tumor cells and macrophages, the most abundant immune cells within the TME. The stable knockdown of ObR (ObR sh) in ERα-positive and ERα-negative BC cells turned the tumor phenotype into a less aggressive one, as evidenced by in vitro and in vivo models.

View Article and Find Full Text PDF

Glioblastoma multiforme (GBM) is the most malignant form of glioma, which represents one of the commonly occurring tumors of the central nervous system. Despite the continuous development of new clinical therapies against this malignancy, it still remains a deadly disease with very poor prognosis. Here, we demonstrated the existence of a biologically active interaction between leptin and Notch signaling pathways that sustains GBM development and progression.

View Article and Find Full Text PDF

Obesity represents a risk factor for breast cancer development and therapy resistance, but the molecular players underling these links are unclear. Here, we identify a role for the obesity-cytokine leptin in sustaining aromatase inhibitor (AI) resistant growth and progression in breast cancer. Using as experimental models MCF-7 breast cancer cells surviving long-term treatment with the AI anastrozole (AnaR) and Ana-sensitive counterparts, we found that AnaR cells expressed higher levels of leptin and its receptors (ObR) along with a constitutive activation of downstream effectors.

View Article and Find Full Text PDF

Obesity is characterized by an excess of adipose tissue, due to adipocyte hypertrophy and hyperplasia. Adipose tissue is an endocrine organ producing many bioactive molecules, called adipokines. During obesity, dysfunctional adipocytes alter adipokine secretion, contributing to pathophysiology of obesity-associated diseases, including metabolic syndrome, type 2-diabetes, cardiovascular diseases and many types of malignancies.

View Article and Find Full Text PDF

This review describes the multifaceted effects of adiponectin on breast cancer cell signalling, tumour metabolism, and microenvironment. It is largely documented that low adiponectin levels are associated with an increased risk of breast cancer. However, it needs to be still clarified what are the extents of the decrease of local/intra-tumoural adiponectin concentrations, which promote breast tumour malignancy.

View Article and Find Full Text PDF

Activation of peroxisome proliferator-activated receptor gamma (PPARγ) elicits anti-proliferative effects on different tumor cells, including those derived from breast cancer. PPARγ is also expressed in several cells of the breast tumor microenvironment, among which tumor associated macrophages (TAMs) play a pivotal role in tumor progression and metastasis. We explored the ability of synthetic and natural PPARγ ligands to modulate TAM polarization.

View Article and Find Full Text PDF
Article Synopsis
  • * Treatment with PDE5 inhibitors reduced the aggressive behavior of cancer-associated fibroblasts (CAFs), impacting tumor growth and interactions between tumor cells and stroma in research models.
  • * Higher levels of PDE5 correlate with increased CXCL16 production from fibroblasts, suggesting it plays a role in tumor stimulation and may serve as a target for improving breast cancer prognosis and treatment.
View Article and Find Full Text PDF

The most frequently diagnosed cancers in women are the estrogen receptor (ER)-positive breast cancer subtypes, which are characterized by estrogen dependency for their growth. The mainstay of clinical treatment for this tumor relies on the modulation of ERα action or on the suppression of estrogen biosynthesis via the administration of Selective ERα Modulators/Down-regulators (SERMs/SERDs) or aromatase inhibitors, respectively. Nevertheless, and acquired resistance to these therapies frequently occurs and represents a major clinical concern for patient survival.

View Article and Find Full Text PDF